

## India : India Responsive COVID-19 Vaccines for Recovery

### 1. Project Information

Project ID:	P000564	Instrument ID:	L0564A
Member:	India	Region:	Southern Asia
Sector:	CRF-Public Health	Sub-sector:	N/A
Instrument type:	<input checked="" type="checkbox"/> Loan:398.23 US Dollar million <input type="checkbox"/> Guarantee	Lead Co-financier (s):	Asian Development Bank
ES category:	C	Borrowing Entity:	Ministry of Finance, India
Implementing Entity:	Ministry of Health and Family Welfare, India		
Project Team Leader:	Ankur Agrawal		
Responsible DG:	Rajat Misra		
Responsible Department:	INF1		
Project Team Members:	Yang Shuai, OSD - Environment & Social Development Specialist; Rabindra Shah, OSD - Procurement Specialist; Yogesh Malla, OSD - Financial Management Specialist; Christopher Damandl, Project Counsel; Jinghui Li, Project admin		
Completed Site Visits by AIIB:			
Planned Site Visits by AIIB:			
Current Red Flags Assigned:	0		
Current Monitoring Regime:	Regular Monitoring		
Previous Red Flags Assigned:	0		
Previous Red Flags Assigned Date:	2023/06		

### 2. Project Summary and Objectives

The objective of the Project was to vaccinate eligible populations against COVID-19 in the selected states of India (project states).

The Project supported the procurement of safe and effective vaccines against COVID-19. The project has been co-financed with the Asian Development Bank (ADB) under the rapid response component of ADB's Asia Pacific Vaccine Access Facility (APVAX).

The total Project cost is USD2.058 billion, for which AIIB finances USD500 million (24.30 percent), ADB finances USD1.5 billion (72.89 percent) and the Government of India (GoI) finances the remaining USD57.77 million (2.81 percent). The loan proceeds from AIIB and ADB financed expenditures relating to the procurement of COVID-19 vaccines that meet the APVAX eligibility criteria. The GoI fund covers financial charges during implementation, including interest, commitment charges and front-end fee. The GoI also provided in-kind contributions in the form of counterpart staff, logistics, cold chain infrastructure, and other facilities.

The Project was expected to procure at least 667 million doses of vaccines to be administered to a target population by 2024 in accordance with the National Deployment Vaccine Plan (NDVP) for COVID-19 vaccines and any subsequent guidelines. The Project was expected to benefit at least 317 million people.

**3. Key Dates**

Approval:	Jan. 20, 2022	Signing:	Jan. 21, 2022
Effective:	Feb. 10, 2022	Restructured (if any):	Jul. 14, 2023
Orig. Closing:	Jun. 30, 2025	Rev. Closing (if any):	Jul. 06, 2023

**4. Disbursement Summary (USD million)**

Contract Awarded:		Cancellation (if any):	101.77
Disbursed:	398.23	Most recent disbursement (amount/date):	25.94/Dec. 27, 2022
Undisbursed:	0.00	Disbursement Ratio (%): <sup>1</sup> :	100.00

**5. Project Implementation Update**

During the reporting period, an additional further loan amount of USD4.58 million was canceled upon the request of the borrower. Since there was no undisbursed loan balance, the loan was closed on July 06, 2023.

Components	Physical Progress	Environmental & Social Compliance	Procurement
Procurement of eligible COVID-19 vaccines	A total of 526.51 million doses of vaccine have been procured under the project utilizing AIIB and ADB loan.	Under ADB's Safeguard Policy Statement (SPS), the project has been categorized as C for Environment, Involuntary Resettlement, and Indigenous Peoples on the basis that no adverse ES impacts are expected. No standalone safeguards monitoring report is required since the project is categorized C for all E&S aspects.	All vaccine procurement contracts have been accomplished under the scope of AIIB financing.

**Financial Management:**

The project audit for FY21-22 is still outstanding. As informed by the borrower, the Comptroller and Auditor General (CAG) is carrying out the audit for the whole program on a cumulative basis (including FY22-23). The timeline for submission of the audit report is not clear.

<sup>1</sup> Disbursement Ratio is defined as the volume (e.g. the dollar amount) of total disbursed amount as a percentage of the net committed volume.

**6. Status of the Grievance Redress Mechanism (GRM)**

---

MOHFW has been operating a toll free 24x7 national helpline '1075' and another helpline (011-23978046) for addressing queries related to the COVID- 19 pandemic, vaccine rollout and the Co-WIN software. In addition to 1075, a technical helpline (0120-4473222) has been established to specifically handle Co-WIN software-related queries. Any technical issue which is not resolved by 1075 is directed to the Technical Helpline for resolution. MOHFW has also created an email ID (ncov2019@gov.in) for addressing COVID-19 related queries and grievances in addition to providing a repository of state COVID-19 helplines and website links for relevant resources, on its website - <https://www.mohfw.gov.in/>. State 104 helplines have been augmented to address queries on COVID-19 vaccination including grievance redressal related to vaccination process as well as linking to concerned facilities for management of any adverse event. As per guidelines, all grievances are to be reviewed at regular intervals at the level of state task force, district task force, urban task force, and block task force.

---

**7. Results Monitoring (please refer to the full RMF, which can be found on the last page of this PIMR)**

---

Results have been achieved proportionate to the loan disbursement

---

**Remarks:**

---

Project Indicators	Objective	Indicator level	Unit of Measure	Cumulative Target Values												Frequency	Responsibility	Comments	
				Baseline		2021		2022		2023		2024		End Target					
				Year	Value	Target	Actual	Target	Actual	Target	Actual	Target	Actual	Year	Target				Actual
At least 317 million targeted people (at least 47.5% women) vaccinated with at least two doses against COVID-19 in project states.	Project	Text	2021	male: 52.6%, female:46.8%, others: 0.6%						263.25 (49.1% female)			2024	317 million, 47.5% of them women			Number of people derived from two dose vaccine.		
By 2024, at least 667 million doses of COVID-19 vaccine procured and delivered to the project states.	Project	Number	2021	0						526.51 million doses			2024	667 million doses			Doses financed by the Project. Total doses administered across the Project states is actually 2.1 billion.		

Project Indicators	Intermediate	Indicator level	Unit of Measure	Cumulative Target Values												Frequency	Responsibility	Comments	
				Baseline		2021		2022		2023		2024		End Target					
				Year	Value	Target	Actual	Target	Actual	Target	Actual	Target	Actual	Year	Target				Actual